Novartis | NVS - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 43.1B 1.46B 2026-09
Amgen USD 23.23B 2.27B 2026-09
AstraZeneca USD 31.27B 286M 2026-09
Bausch Health Companies USD 4.75B 205M 2026-09
Biogen USD 3.9B 18.7M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Canopy Growth CAD 166.75M 8.31M 2026-06
Corcept Therapeutics USD 177.68M 23.87M 2026-09
Drreddys Laboratories INR 154.49B 13.08B 2026-09
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
J&J USD 55.46B 562M 2026-09
Merck USD 28.8B 1.07B 2026-09
Novartis USD 32.52B 777M 2026-09
Novartis USD 32.52B 1.15B 2026-09
Pacira USD 126.1M 4.08M 2026-09
Perrigo USD 1.02B 34.4M 2026-09
Pfizer USD 31.73B 920M 2026-09
Phibro Animal Health USD 295.79M 20.68M 2026-09
Prestige Brands USD 168.5M 14.7M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 29.77B 2.16B 2026-09
Sanofi EUR 31.93B 1.92B 2026-06
Supernus Pharmaceuticals USD 285.4M 61.98M 2026-09
Zoetis USD 2.68B 621M 2026-09